TABLE 3

Summary of randomised controlled trials with anti-interleukin-5 treatment: eosinophil threshold used in each trial and percentage of atopics in enrolled patients

First author [ref.]YearTreatmentEosinophil thresholdPatients nAtopic
Haldar [24]2009Mepolizumab>3% sputum eosinophils6168% SPT+
Castro [54]2011Reslizumab>3% sputum eosinophils10680% allergic rhinitis
Pavord [15]2012Mepolizumab>300 μL−1 blood eosinophils61650% SPT+
Ortega [55]2014Mepolizumab>150 μL−1 blood eosinophils at screening or >300 μL−1 during previous year57649% allergic rhinitis
Bel [56]2014Mepolizumab>300 μL−1 blood eosinophils13546% allergic rhinitis
Castro [58]2014BenralizumabNo threshold for eosinophils; FENO >50 ppb used as surrogate marker244Not reported
Castro [57]2015Reslizumab>400 μL−1 blood eosinophils953Not reported
Corren [66]2016ReslizumabNo initial threshold for eosinophils; ≥400 μL−1 blood eosinophils as clinically significant492Not reported
Bjermer [65]2016Reslizumab≥400 μL−1 blood eosinophils315Not reported
FitzGerald [60]2016BenralizumabNo initial threshold for eosinophils; ≥300 μL−1 blood eosinophils as clinically significant130662% RAST+
Bleecker [59]2016BenralizumabNo initial threshold for eosinophils; ≥300 μL−1 blood eosinophils as clinically significant120463% RAST+

SPT: skin prick test; FENO: exhaled nitric oxide fraction; RAST: radioallergosorbent test.